Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 8/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31628652 | 0.84 | RXRA (0.42) | DDB1CRBNALDH1A1LMNAPOLB | |
| SCHEMBL1193030 | 0.84 | RXRA (0.42) | DDB1CRBNALDH1A1LMNAPOLB | |
| SCHEMBL476884 | 0.84 | RXRA (0.42) | DDB1CRBNALDH1A1LMNAPOLB | |
| SCHEMBL156398 | 0.84 | RXRA (0.42) | DDB1CRBNALDH1A1LMNAPOLB | |
| SCHEMBL29416187 | 0.84 | RXRA (0.42) | DDB1CRBNALDH1A1LMNAPOLB | |
| SCHEMBL1141884 | 0.84 | RXRA (0.45) | DDB1CRBNALDH1A1LMNAPOLB | |
| SCHEMBL4572292 | 0.84 | CYP4F2 (0.46) | ALDH1A1LMNAPOLBRXRARXRB | |
| SCHEMBL3868044 | 0.83 | RXRA (0.43) | DDB1CRBNALDH1A1LMNAPOLB | |
| SCHEMBL27764686 | 0.83 | RXRA (0.42) | DDB1CRBNALDH1A1LMNAPOLB | |
| SCHEMBL22499301 | 0.82 | RXRA (0.44) | DDB1CRBNALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612387-B2 | RAS inhibitors and methods of using the same | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2026-04-28 | — | — | US | disclosed |
| US-12435090-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use | REPARE THERAPEUTICS INC. (CA) | 2025-10-07 | — | — | US | disclosed |
| US-20230339910-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339910-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339910-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-10-26 | — | — | US | disclosed |
| US-20230122909-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE | REPARE THERAPEUTICS INC. (CA) | 2023-04-20 | — | — | US | disclosed |
| EP-4097095-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | Jazz Pharmaceuticals Ireland Limited (IE) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021152149-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2021-08-05 | — | — | WO | disclosed |
| EP-2424859-B1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2424859-B1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | AMGEN INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8362241-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362241-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362241-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2424859-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | Amgen, Inc (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126895-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010126895-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | MTOR, PIK3CA, PIK3CD | DDB1 3458/4885CRBN 1445/4885ALDH1A1 4256/4885 |
| US-20230122909-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE | PLK1, CSNK1A1, CSNK1G1 | DDB1 840/4885CRBN 571/4885ALDH1A1 4093/4885 |
| US-12612387-B2 | RAS inhibitors and methods of using the same | KRAS, NRAS, HRAS | DDB1 144/4885CRBN 238/4885ALDH1A1 2058/4885 |
| US-20230339910-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | DDB1 165/4885CRBN 851/4885ALDH1A1 3682/4885 |
| US-12435090-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use | PLK1, CSNK1A1, CSNK1G1 | DDB1 840/4885CRBN 571/4885ALDH1A1 4093/4885 |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | MTOR, PIK3CA, PIK3CD | DDB1 3458/4885CRBN 1445/4885ALDH1A1 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.